Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders
Shots:
- The companies collaborated to advance the targeted delivery of AT-04, a novel pan-amyloid removal candidate across the blood-brain barrier (BBB) by using Ossianix' patented VNAR antibody-based brain shuttle TXP1 for the treatment of neurodegenerative disorders i.e., AD
- The technology is designed to improve CNS penetration and efficacy along with lowering dosage and side effects. In the preclinical studies, AT-04 showed a potent binding to multiple types of amyloid, Aβ, tau, and α-synuclein fibrils in neurodegenerative disorders
- AT-04 is a fusion of the Company's PAR-peptide technology with the Fc component of a human IgG1 Ab
Ref: Globenewswire | Image: Attralus
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
